Equities Analysts Offer Predictions for QNCX FY2024 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Equities research analysts at Brookline Capital Management issued their FY2024 earnings per share estimates for Quince Therapeutics in a report issued on Wednesday, December 18th. Brookline Capital Management analyst K. Raja anticipates that the company will post earnings of ($1.21) per share for the year. Brookline Capital Management has a “Buy” rating and a $9.00 price objective on the stock. Brookline Capital Management also issued estimates for Quince Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.52 EPS.

Several other research firms have also commented on QNCX. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Rodman & Renshaw started coverage on shares of Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Maxim Group initiated coverage on shares of Quince Therapeutics in a research note on Thursday, November 7th. They set a “buy” rating and a $6.00 price target on the stock. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Quince Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.67.

Quince Therapeutics Stock Performance

Shares of Quince Therapeutics stock opened at $1.78 on Friday. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The firm’s fifty day simple moving average is $1.61 and its 200-day simple moving average is $1.03. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market capitalization of $78.32 million, a price-to-earnings ratio of -1.44 and a beta of 0.74.

Institutional Investors Weigh In On Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC raised its position in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned approximately 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.